Graves' disease
Conditions
Interventions
Test group:receiving ultrasound-guided microwave ablation
Sponsors
Cancer Hospital of Shantou University Medical College
Eligibility
Sex/Gender
All
Age
13 Years to 69 Years
Inclusion criteria
Inclusion criteria: 1.diagnosis of Grave's disease according to the 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosi; 2.treatment with methimazole (with or without ß-adrenergic blocker) for more than 18 months prior to ablation; 3.normal blood count, biochemistry, coagulation, and thyroid function before the start of microwave ablation;
Exclusion criteria
Exclusion criteria: 1.patients with a clear surgical indication (such as compressive goiter, suspected or documented thyroid malignancy or moderate to severe Graves’ ophthalmopathy); 2.patients with a higher risk of receiving MWA (such as severe cardiovascular and cerebrovascular diseases, liver and kidney insufficiency, or coagulation dysfunction); withdrawal methimazole because of severe adverse effects or other reasons; 3.experiencing conditions that may affect thyroid functions, such as pregnancy;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| thyroid volume;thyrotropin;free triiodothyronine;total triiodothyronine;free tetraiodothyronine;total tetraiodothyronine; | — |
Countries
China
Contacts
Public ContactHanwei Peng
Department of Head and Neck Surgery, Cancer Hospital of Shantou University Medical College, Shantou City, Guangdong Province, China.
Outcome results
None listed